Interested in becoming an advocate?
Mounjaro®
Once a week subcutaneous injection
Ozempic (generic name: Semaglutide) is a GLP-1 agonist FDA approved for the treatment of type 2 diabetes.
Mounjaro (generic name: Tirzepatide) is a GLP-1/GIP receptor agonist drug and one of the newer medications that can result in substantial weight loss. It is currently FDA approved for type 2 diabetes.
How does
Mounjaro®
work:
- act on brain signaling to reduce food intake
- helps control blood sugar levels by increasing the release of insulin from the pancreas
- slows down food leaving your stomach, thus, keeping you fuller for longer
Common side effects of
Mounjaro®
- nausea
- vomiting
- diarrhea
- decreased appetite
- stomach (abdominal) pain
- constipation
You can find more information here:
Expected Results:
- Helps control blood sugar levels
- Decreased HgbA1C
- Although Mounjaro hasn’t been FDA approved for weight loss, studies have shown that adults on Mounjaro lost on average 21% of their body weight after 72 weeks.
Do not take
Mounjaro®
if you:
- have or any of your family members have ever had medullary thyroid carcinoma (MTC) or if you have MEN2
- are pregnant, planning to become pregnant or breastfeeding
- have or have had history of pancreatitis
- history of chronic malabsorption
- history of gallbladder disease
- have a history of gastroparesis or IBD
- are allergic to tirzepatide or any of the ingredients* in Mounjaro
*non-medicinal ingredients in Mounjaro: Sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH.
Disclaimer: Please note that the following list may not encompass all potential side effects or drug interactions. To determine if any drug or supplement you are currently taking could interact with a medication, we strongly advise consulting your healthcare provider or pharmacist. Seek medical advice immediately if you experience any adverse reaction.